David Matuskey, MD
Associate Professor of Radiology and Biomedical ImagingDownloadHi-Res Photo
Cards
Appointments
Additional Titles
Director, NeuroPET Imaging Program, Radiology and Biomedical Imaging
Medical Director, Yale Positron Emission Tomography (PET) Center
Contact Info
Appointments
Additional Titles
Director, NeuroPET Imaging Program, Radiology and Biomedical Imaging
Medical Director, Yale Positron Emission Tomography (PET) Center
Contact Info
Appointments
Additional Titles
Director, NeuroPET Imaging Program, Radiology and Biomedical Imaging
Medical Director, Yale Positron Emission Tomography (PET) Center
Contact Info
About
Titles
Associate Professor of Radiology and Biomedical Imaging
Director, NeuroPET Imaging Program, Radiology and Biomedical Imaging; Medical Director, Yale Positron Emission Tomography (PET) Center
Biography
I am a board certified psychiatrist and neuropsychiatrist with research work that has been translational in nature and focused on elucidating the underlying pathology of brain conditions such as Autism Spectrum Disorder, substance abuse and neuropsychiatric disorders (e.g., Parkinson's disease) with an aim to find effective clinical treatments guided by molecular neuroimaging. Studies have included using in vivo PET imaging to investigate the role of neuroreceptors such as dopamine D3, serotonin 1B and 6, MGlur5 and kappa opioid systems, neuroinflammation, and most recently, synaptic density (SV2A) in clinical and nonclinical populations. Ongoing interests include imaging neuropsychiatric and addictive disorders and the demographic, social and environmental factors influencing our brain.
Appointments
Radiology & Biomedical Imaging
Associate Professor on TermPrimaryNeurology
Assistant ProfessorSecondaryNeurology
Associate Professor on TermSecondaryPsychiatry
Associate Professor on TermSecondary
Other Departments & Organizations
- Bioimaging Sciences
- Center for Brain & Mind Health
- Connecticut Mental Health Center
- Mental Health PET Radioligand Development (MHPRD) Program
- Movement Disorders
- MR Core
- Neurology
- NeuroPET Imaging Program
- PET Core
- Psychiatric Symptoms in Neurology Research Program
- Psychiatry
- Radiology & Biomedical Imaging
- Yale Biomedical Imaging Institute
- Yale Cocaine Research Clinic
Education & Training
- Clinical Neuroscience Research Fellow
- Yale University (2010)
- Senior Resident
- Yale University (2009)
- Resident
- University of Connecticut (2008)
- MD
- St Matthew's University School of Medicine (2005)
- BA
- University of South Florida, Psychology (1998)
- BS
- University of South Florida, Biology (1998)
Research
Overview
Medical Research Interests
Addiction Medicine; Autistic Disorder; Essential Tremor; Frontotemporal Dementia; Meditation; Mental Disorders; Molecular Imaging; Neuroimaging; Neuropsychiatry; Parkinson Disease; Social Class
Public Health Interests
Mental Health; Global Health
ORCID
0000-0001-7508-6572
Research at a Glance
Yale Co-Authors
Frequent collaborators of David Matuskey's published research.
Publications Timeline
A big-picture view of David Matuskey's research output by year.
Research Interests
Research topics David Matuskey is interested in exploring.
Nabeel Nabulsi, PhD
Richard Carson, PhD
Jean-Dominique Gallezot, PhD
Irina Esterlis, PhD
Shannan Henry
Yiyun Huang, PhD
77Publications
3,104Citations
Neuroimaging
Mental Disorders
Social Class
Molecular Imaging
Publications
2025
Air Pollution and Dopamine in Parkinson’s Disease (S21.001)
Saraiya R, Cayir S, Pala V, Tezel M, Solomon B, Elshahat A, Matuskey D. Air Pollution and Dopamine in Parkinson’s Disease (S21.001). Neurology 2025, 104 DOI: 10.1212/wnl.0000000000208890.Peer-Reviewed Original ResearchCerebrospinal Fluid Biomarkers and Cognition in Alzheimer Disease and Frontotemporal Dementia in a Memory Clinic Setting
Cayir S, Sadabad F, Mecca A, Matuskey D, Fesharaki-Zadeh A. Cerebrospinal Fluid Biomarkers and Cognition in Alzheimer Disease and Frontotemporal Dementia in a Memory Clinic Setting. Alzheimer Disease & Associated Disorders 2025, 39: 22-27. DOI: 10.1097/wad.0000000000000656.Peer-Reviewed Original ResearchConceptsMoCA scoresMemory clinic settingHospital memory clinicCognitive performanceMontreal Cognitive AssessmentFrontotemporal dementiaAlzheimer's diseaseCognitive test scoresP-tauMemory clinicElectronic records of patientsRetrospective cohort studyT-tauCohort studyCognitive AssessmentElectronic recordsMoCACerebrospinal fluidRecords of patientsIndex scoreTau-related pathologyClinical settingDementiaConcentrations of T-tauScores
2024
Quantitative Accuracy Assessment of the NeuroEXPLORER for Diverse Imaging Applications: Moving Beyond Standard Evaluations.
Omidvari N, Shanina E, Leung E, Sun X, Li Y, Mulnix T, Gravel P, Henry S, Matuskey D, Volpi T, Jones T, Badawi R, Li H, Carson R, Qi J, Cherry S. Quantitative Accuracy Assessment of the NeuroEXPLORER for Diverse Imaging Applications: Moving Beyond Standard Evaluations. Journal Of Nuclear Medicine 2024, 66: 150-157. PMID: 39638433, PMCID: PMC11705792, DOI: 10.2967/jnumed.124.268309.Peer-Reviewed Original ResearchConceptsContrast recovery coefficientHoffman phantomUniform phantomIQ phantomRecovery coefficientBrain PET systemHoffman brain phantomBrain uptakeSpatial resolutionDiverse imaging applicationsCylindrical phantomPET systemBrain phantomNeuroimaging studiesImage qualityImaging conditionsPhantomReconstruction parametersImaging time pointsTime pointsImage-derived input functionHigher spatial resolutionQuantitative accuracyDelayed time pointsBrain disordersAn In Vivo Examination of the Relationship Between Metabotropic Glutamate 5 Receptor and Suicide Attempts in People With Borderline Personality Disorder
Davis M, Asch R, Weiss E, Wagner A, Fineberg S, Nabulsi N, Matuskey D, Carson R, Esterlis I. An In Vivo Examination of the Relationship Between Metabotropic Glutamate 5 Receptor and Suicide Attempts in People With Borderline Personality Disorder. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2024, 10: 324-332. PMID: 39613160, DOI: 10.1016/j.bpsc.2024.11.014.Peer-Reviewed Original ResearchConceptsBorderline personality disorderPathophysiology of borderline personality disorderSuicide attemptsPersonality disorderPositron emission tomographyAssociated with history of suicide attemptBorderline personality disorder symptomsBPD pathophysiologyPositron emission tomography outcomes measurementsHistory of suicide attemptsMetabotropic glutamate receptor type 5Metabotropic glutamate receptor 5Glutamate receptor 5Comprehensive clinical assessmentFrontolimbic circuitsMDD groupDepressive disorderEmotion regulationPsychiatric conditionsCognitive functionMGlu5Comparison controlsMDDSuicideAssociated with history11C-UCB-J PET imaging is consistent with lower synaptic density in autistic adults
Matuskey D, Yang Y, Naganawa M, Koohsari S, Toyonaga T, Gravel P, Pittman B, Torres K, Pisani L, Finn C, Cramer-Benjamin S, Herman N, Rosenthal L, Franke C, Walicki B, Esterlis I, Skosnik P, Radhakrishnan R, Wolf J, Nabulsi N, Ropchan J, Huang Y, Carson R, Naples A, McPartland J. 11C-UCB-J PET imaging is consistent with lower synaptic density in autistic adults. Molecular Psychiatry 2024, 30: 1610-1616. PMID: 39367053, DOI: 10.1038/s41380-024-02776-2.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPositron emission tomographySynaptic densityAutistic adultsBrain regionsAutistic featuresClinical phenotype of autismNon-autistic participantsPhenotype of autismNon-autistic individualsRelationship to clinical characteristicsSynaptic vesicle glycoprotein 2AAssociated with clinical measuresPost-mortem studiesPositron emission tomography scanPrefrontal cortexClinician ratingsAutism groupNeural basisBrain areasNeural processesBetween-group differencesVolumetric differencesBinding potentialDensity of synapsesAutismSocioenvironmental Factors are Associated With Dopamine Transporter Availability in Healthy Individuals but not in Parkinson’s Disease
Cayir S, Tezel M, Matuskey D. Socioenvironmental Factors are Associated With Dopamine Transporter Availability in Healthy Individuals but not in Parkinson’s Disease. Journal Of Geriatric Psychiatry And Neurology 2024, 38: 143-149. PMID: 39244698, DOI: 10.1177/08919887241281062.Peer-Reviewed Original ResearchAltmetricConceptsMedian household incomeDopaminergic functionHealthy individualsSocioenvironmental factorsEducation levelHousehold incomeZIP Code Tabulation AreasBrain dopaminergic functionDopamine transporter availabilityResidential zip codeParkinson's Progression Markers InitiativeParkinson's diseaseNo significant associationAmerican Community SurveyDAT availabilityDopamine transporterZip codesClinical dataHealthy subjectsSocioenvironmental variablesCommunity SurveySignificant associationPD groupPoverty ratesStudy findingsClinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights
Honhar P, Sadabad F, Tinaz S, Gallezot J, Dias M, Naganawa M, Yang Y, Henry S, Hillmer A, Gao H, Najafzadeh S, Comley R, Nabulsi N, Huang Y, Finnema S, Carson R, Matuskey D. Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights. Brain Communications 2024, 6: fcae345. PMID: 39429243, PMCID: PMC11487911, DOI: 10.1093/braincomms/fcae345.Peer-Reviewed Original ResearchCitationsConceptsDAT availabilityMotor severitySubstantia nigraDopamine transporter availabilityClinical trials of Parkinson's diseaseParkinson's diseaseLongitudinal studyTracking longitudinal changesClinical correlatesVentral striatumTransporter availabilityNigrostriatal regionParkinson's disease patientsPutamenMotor severity scoresAssociated with increasesSubstantiaDATLongitudinal changesTremor scoreNegative associationNigraSubstantia nigra of Parkinson's disease patientsTremor severityPET biomarkersNoninvasive quantification of [18F]SynVesT-1 binding using simplified reference tissue model 2
Naganawa M, Gallezot J, Li S, Nabulsi N, Henry S, Cai Z, Matuskey D, Huang Y, Carson R. Noninvasive quantification of [18F]SynVesT-1 binding using simplified reference tissue model 2. European Journal Of Nuclear Medicine And Molecular Imaging 2024, 52: 113-121. PMID: 39155309, DOI: 10.1007/s00259-024-06885-6.Peer-Reviewed Original ResearchCitationsConceptsPositron emission tomographyCentrum semiovaleReference regionPositron emission tomography scanTest-retest variabilityTest-retest reproducibilitySynaptic vesicle glycoprotein 2AOne-tissue compartmentArterial blood samplesRetest scansGold standardBrain uptakeEmission tomographyBlood samplesCerebellumNoninvasive quantificationSRTM2ConclusionOur findingsPopulation averageHealthy participantsMetabolite analysisScan timeBPNDSemiovalePerformance Characteristics of the NeuroEXPLORER, a Next-Generation Human Brain PET/CT Imager
Li H, Badawi R, Cherry S, Fontaine K, He L, Henry S, Hillmer A, Hu L, Khattar N, Leung E, Li T, Li Y, Liu C, Liu P, Lu Z, Majewski S, Matuskey D, Morris E, Mulnix T, Omidvari N, Samanta S, Selfridge A, Sun X, Toyonaga T, Volpi T, Zeng T, Jones T, Qi J, Carson R. Performance Characteristics of the NeuroEXPLORER, a Next-Generation Human Brain PET/CT Imager. Journal Of Nuclear Medicine 2024, 65: jnumed.124.267767. PMID: 38871391, PMCID: PMC11294061, DOI: 10.2967/jnumed.124.267767.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPeak noise-equivalent count rateNoise-equivalent count rateTime-of-flight resolutionField of viewCount rateExtended axial field-of-viewTransverse field-of-viewAxial field-of-viewField-of-view centerMini-Derenzo phantomSpatial resolutionTangential spatial resolutionsCount rate performanceContrast recovery coefficientHuman brain PET imagingMeasurements of spatial resolutionNEMA sensitivityEnergy resolutionScatter fractionBrain phantomBackprojection reconstructionBrain PET imagingTime resolutionRadial offsetF-FDG imagingTreatment resistant depression in a young female successfully treated with a combination of ketamine and pramipexole – A case report
Ibrahim W, Yang Y, Matuskey D. Treatment resistant depression in a young female successfully treated with a combination of ketamine and pramipexole – A case report. Psychiatry Research Case Reports 2024, 3: 100228. DOI: 10.1016/j.psycr.2024.100228.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionForced swim testResistant depressionAntidepressant medicationAdequate trial of antidepressant medicationClasses of antidepressant medicationsTrials of antidepressant medicationsMesolimbic dopaminergic pathwayPatients' depressive symptomsD2/3 receptorsSwim testMood stabilizersDopaminergic pathwaysElectroconvulsive therapyDepressive symptomsAdequate trialKetamine infusionDopamine deficiencyFailure of treatmentDepressionYoung adult femalesPramipexoleCase reportPreclinical studiesKetamine
Clinical Trials
Current Trials
Brain Connections & HIV Status
HIC ID2000033582RoleSub InvestigatorPrimary Completion Date12/31/2027Recruiting ParticipantsGenderBothAge18 years - 80 yearsMeditation and Synaptic Density
HIC ID2000030601RolePrincipal InvestigatorPrimary Completion Date08/31/2024Recruiting ParticipantsGenderBothAge28 years - 70 yearsM1 Schizophrenia PET Study
HIC ID2000031171RoleSub InvestigatorPrimary Completion Date04/30/2023Recruiting ParticipantsGenderBothAge18 years - 55 yearsKetamine for the Treatment of Depression in Parkinson's Disease
HIC ID2000030394RoleSub InvestigatorPrimary Completion Date08/31/2024Recruiting ParticipantsGenderBothAge40 years - 70 yearsImaging cortisol metabolism in liver, adipose tissue and brain with a novel PET radioligand
HIC ID2000029576RoleSub InvestigatorPrimary Completion Date06/30/2024Recruiting Participants
Academic Achievements & Community Involvement
Honors
honor NARSAD Young Investigator Award
08/07/2018National AwardBrain & Behavior Research FoundationDetailsUnited Stateshonor Michael Kuhar Travel Award
08/23/2011International AwardInternational Drug and Alcohol Research SocietyDetailsUnited Stateshonor NIDA-ISAM Travel Fellowship
01/01/2011International AwardNIDA-ISAMDetailsUnited Stateshonor NARSAD Young Investigator Award
08/01/2010National AwardBrain & Behavior Research FoundationDetailsUnited States
News
News
- October 15, 2024
A Key Brain Difference Linked to Autism Is Found for the First Time in Living People
- January 29, 2023
Symposium Highlights Importance of Biomedical Imaging for Understanding Neurological Disease
- November 15, 2022Source: Biological Psychiatry
Yale Study Seeks to Understand Neurobiology Underlying Bipolar Disorder Vs. Major Depressive Disorder
- November 15, 2021
Michael J. Fox Foundation Grant Will Fund First Clinical Trial of Ketamine to Treat Depression in People With Parkinson’s Disease
Get In Touch
Contacts
Academic Office Number
Locations
801 Howard Avenue
Academic Office
New Haven, CT 06519